Between September and October this year, Seattle Genetics is expecting results from up to 3 clinical trials -- each of which could result in an NDA filing. Two of the trials are with its lead compound SGN-35, brentuximab vedotin, an antibody drug conjugate. SGN-35 is in clinical trials for the treatment of two CD30 targets -- refractory Hodgkin's Lymphoma and anaplastic large cell lymphoma (ALCL). Takeda's Millenium paid $60 M upfront with up to $230 M in milestones for SGN-35 earlier in 2010.
Seattle Genetics other lead candidate is SGN-33, lintuzumab, directed against CD33 found in AML and MDS cancer cells. SGN-33 may give these patients another treatment option besides cytarbine which is not tolerated well in patients over 65. Celgene's competitive product Vidaza is currently expected to reach sales of $500 M for these applications -- indicating good potential for SGN-33 too.
Read full report in Seeking Alpha.
Posted by Bruce Lehr August 6th 2010.
Comments